Organisation paid for research Program year 2025 Source: CMS Open Payments

Parkview Research Center

Neither a doctor nor a teaching hospital

Research payments

$2,349,497

73 payments

Through program year 2025, Parkview Research Center is reported as receiving $2,349,497 in research payments, across 73 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $501,564 11
2024 Research $473,355 14
2023 Research $799,458 9
2022 Research $280,314 17
2021 Research $181,626 11
2020 Research $103,994 8
2019 Research $9,187 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,684,103 20 payments
  2. GlaxoSmithKline, LLC. $483,713 29 payments
  3. Medtronic, Inc. $90,974 9 payments
  4. Merck Sharp & Dohme Corporation $45,014 5 payments
  5. Karyopharm Therapeutics Inc. $38,927 7 payments
  6. Covidien LP $6,187 1 payment
  7. AstraZeneca UK Limited $575 1 payment
  8. Amgen Inc. $5 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. An Open-Label, Randomized, Phase III Study Comparing 177Lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) $885,002 5 payments
  2. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $581,341 6 payments
  3. A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab $483,713 29 payments
  4. A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment (VAYHIT2) $117,418 2 payments
  5. Alleviate-Hf $90,974 9 payments
  6. A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1) $47,102 2 payments
  7. A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer NSCLC $39,084 1 payment
  8. A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer $38,927 7 payments
  9. A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment $30,699 2 payments
  10. A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer $22,297 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record